Stock listing
Tradegate:LX31 Lexicon Pharmaceuticals, Inc. Aktie
German listing (Tradegate) of Lexicon Pharmaceuticals, Inc. · home listing NASDAQ:LXRX
Follow Lexicon Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:LXRX
$1.49 USD -0.07 (-4.5%)
Close on Oct 22, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:LXRX
- Day range
- $1.48 – $1.59 USDOct 22, 2026
- Volume
- 1.32M sharesOct 22, 2026
- Market cap
- $663.0M USDAt the close on Oct 22, 2026 · price × 445.0M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LXRX · Home | $1.49 USD | -0.07 (-4.5%) | 1,319,561 | $1.56 | $1.585 | $1.48 | $1.56 | Close on Oct 22, 2026 |
Daily closes
Last 3 months, Jul 22, 2026 – Oct 22, 2026 · NASDAQ:LXRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.49 | -0.07 | -4.5% | $1.56 | $1.585 | $1.48 | 1,319,561 | |
| $1.56 | -0.02 | -1.3% | $1.59 | $1.617 | $1.545 | 1,395,519 | |
| $1.58 | +0.03 | +1.9% | $1.56 | $1.63 | $1.545 | 1,410,971 | |
| $1.55 | +0.03 | +2.0% | $1.54 | $1.58 | $1.515 | 1,723,467 | |
| $1.52 | -0.13 | -7.9% | $1.68 | $1.68 | $1.52 | 2,006,303 | |
| $1.65 | +0.05 | +3.1% | $1.63 | $1.675 | $1.62 | 1,433,302 | |
| $1.60 | -0.01 | -0.6% | $1.61 | $1.63 | $1.56 | 1,902,900 | |
| $1.61 | -0.04 | -2.4% | $1.65 | $1.655 | $1.59 | 2,049,798 | |
| $1.65 | -0.03 | -1.8% | $1.65 | $1.67 | $1.61 | 2,027,800 | |
| $1.68 | -0.08 | -4.5% | $1.75 | $1.77 | $1.67 | 2,066,000 | |
| $1.76 | 0.00 | 0.0% | $1.75 | $1.78 | $1.70 | 3,319,500 | |
| $1.76 | +0.01 | +0.6% | $1.73 | $1.77 | $1.71 | 1,100,100 | |
| $1.75 | +0.01 | +0.6% | $1.75 | $1.78 | $1.72 | 1,640,400 | |
| $1.74 | -0.08 | -4.4% | $1.83 | $1.83 | $1.72 | 2,716,300 | |
| $1.82 | 0.00 | 0.0% | $1.85 | $1.87 | $1.80 | 2,316,700 | |
| $1.82 | -0.06 | -3.2% | $1.86 | $1.87 | $1.81 | 2,273,000 | |
| $1.88 | 0.00 | 0.0% | $1.89 | $1.95 | $1.84 | 1,744,200 | |
| $1.88 | -0.02 | -1.1% | $1.92 | $1.94 | $1.80 | 3,945,200 | |
| $1.90 | +0.10 | +5.6% | $1.88 | $2.05 | $1.81 | 10,888,800 | |
| $1.80 | -0.06 | -3.2% | $1.87 | $1.93 | $1.77 | 3,050,400 | |
| $1.86 | -0.20 | -9.7% | $2.05 | $2.06 | $1.85 | 4,441,600 | |
| $2.06 | -0.12 | -5.5% | $2.17 | $2.17 | $2.02 | 3,172,100 | |
| $2.18 | +0.14 | +6.9% | $2.05 | $2.20 | $2.02 | 4,843,800 | |
| $2.04 | -0.01 | -0.5% | $2.05 | $2.08 | $2.00 | 2,506,500 | |
| $2.05 | +0.01 | +0.5% | $2.04 | $2.06 | $1.99 | 7,458,700 | |
| $2.04 | +0.02 | +1.0% | $2.05 | $2.11 | $2.02 | 2,235,700 | |
| $2.02 | +0.01 | +0.5% | $2.01 | $2.06 | $2.00 | 2,151,600 | |
| $2.01 | +0.03 | +1.5% | $1.98 | $2.02 | $1.89 | 2,508,500 | |
| $1.98 | -0.02 | -1.0% | $1.97 | $2.01 | $1.94 | 1,773,800 | |
| $2.00 | -0.02 | -1.0% | $2.05 | $2.06 | $1.95 | 3,722,700 | |
| $2.02 | -0.13 | -6.0% | $2.11 | $2.14 | $2.01 | 2,938,300 | |
| $2.15 | -0.08 | -3.6% | $2.21 | $2.23 | $2.13 | 2,204,300 | |
| $2.23 | -0.01 | -0.4% | $2.22 | $2.25 | $2.19 | 1,656,800 | |
| $2.24 | -0.02 | -0.9% | $2.25 | $2.26 | $2.22 | 1,043,700 | |
| $2.26 | +0.02 | +0.9% | $2.25 | $2.27 | $2.23 | 1,507,100 | |
| $2.24 | +0.05 | +2.3% | $2.21 | $2.27 | $2.19 | 2,335,900 | |
| $2.19 | -0.06 | -2.7% | $2.24 | $2.27 | $2.17 | 1,987,400 | |
| $2.25 | -0.04 | -1.7% | $2.27 | $2.29 | $2.19 | 6,647,500 | |
| $2.29 | -0.03 | -1.3% | $2.30 | $2.32 | $2.26 | 2,677,200 | |
| $2.32 | +0.01 | +0.4% | $2.30 | $2.34 | $2.30 | 1,616,400 | |
| $2.31 | -0.03 | -1.3% | $2.32 | $2.35 | $2.28 | 1,197,700 | |
| $2.34 | +0.02 | +0.9% | $2.35 | $2.365 | $2.30 | 1,821,248 | |
| $2.32 | +0.02 | +0.9% | $2.32 | $2.35 | $2.295 | 1,675,637 | |
| $2.30 | +0.12 | +5.5% | $2.19 | $2.31 | $2.19 | 3,193,900 | |
| $2.18 | -0.23 | -9.5% | $2.40 | $2.40 | $2.17 | 4,746,500 | |
| $2.41 | -0.01 | -0.4% | $2.46 | $2.48 | $2.39 | 1,776,100 | |
| $2.42 | +0.08 | +3.4% | $2.33 | $2.44 | $2.33 | 2,904,900 | |
| $2.34 | +0.02 | +0.9% | $2.31 | $2.39 | $2.29 | 3,530,400 | |
| $2.32 | -0.02 | -0.9% | $2.32 | $2.34 | $2.27 | 1,762,700 | |
| $2.34 | -0.01 | -0.4% | $2.37 | $2.39 | $2.32 | 2,315,200 | |
| $2.35 | -0.08 | -3.3% | $2.41 | $2.46 | $2.35 | 2,569,100 | |
| $2.43 | +0.03 | +1.3% | $2.42 | $2.45 | $2.31 | 3,031,700 | |
| $2.40 | -0.07 | -2.8% | $2.45 | $2.49 | $2.38 | 2,696,700 | |
| $2.47 | +0.11 | +4.7% | $2.44 | $2.48 | $2.29 | 3,085,700 | |
| $2.36 | -0.09 | -3.7% | $1.96 | $2.44 | $1.96 | 4,890,800 | |
| $2.45 | -0.04 | -1.6% | $2.52 | $2.52 | $2.40 | 3,974,300 | |
| $2.49 | +0.16 | +6.9% | $2.33 | $2.52 | $2.32 | 3,908,900 | |
| $2.33 | +0.02 | +0.9% | $2.29 | $2.34 | $2.22 | 2,052,700 | |
| $2.31 | -0.03 | -1.3% | $2.32 | $2.35 | $2.25 | 2,768,000 | |
| $2.34 | +0.02 | +0.9% | $2.32 | $2.40 | $2.29 | 2,463,100 | |
| $2.32 | -0.02 | -0.9% | $2.38 | $2.42 | $2.29 | 2,476,100 | |
| $2.34 | +0.11 | +4.9% | $2.24 | $2.35 | $2.17 | 2,678,800 | |
| $2.23 | -0.06 | -2.6% | $2.30 | $2.38 | $2.16 | 2,956,400 | |
| $2.29 | -0.01 | -0.4% | $2.30 | $2.35 | $2.24 | 1,681,800 | |
| $2.30 | +0.05 | +2.2% | $2.21 | $2.35 | $2.19 | 2,708,500 | |
| $2.25 | -0.13 | -5.5% | $2.36 | $2.37 | $2.19 | 3,601,900 |
- Ticker
- Tradegate:LX31
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Tradegate
- Currency
- EUR
What changed lately
Latest news release · Oct 21, 2026
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
Latest earnings call · Aug 6, 2026
Lexicon Pharmaceuticals (NASDAQ:LXRX) Q2 2026 Earnings Call
Replay and transcript
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 32 slides
Calls
Replays
Lexicon Pharmaceuticals (NASDAQ:LXRX) Q2 2026 Earnings Call
Thu, Aug 06, 2026 · 8:30 AM ET
Watch TranscriptLexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2026 Earnings Call
Thu, May 07, 2026 · 8:30 AM ET
Watch TranscriptLexicon Pharmaceuticals (NASDAQ:LXRX) Q4 2025 Earnings Call
Thu, Mar 05, 2026 · 8:30 AM ET
Watch Transcript
Latest news
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
Oct 21, 2026
Closed $1.56 (-1.3%) on Oct 21, 2026
LX-9211 Market Outlook 2026-2034 | Sales Forecast Highlights Emerging Commercial Opportunities
Sep 25, 2026
Closed $1.80 (-3.2%) on Sep 25, 2026
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
Sep 1, 2026
Closed $2.24 (+2.3%) on Sep 2, 2026
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
Aug 31, 2026
Closed $2.25 (-1.7%) on Aug 31, 2026
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
Aug 24, 2026
Closed $2.32 (+0.9%) on Aug 24, 2026
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Aug 7, 2026
Closed $2.47 (+4.7%) on Aug 7, 2026
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Jul 30, 2026
Closed $2.34 (+0.9%) on Jul 30, 2026
Decks
Investor Presentation (September 2026)
Investor deck · 32 slides · September 2026
Q2 2026 Earnings Presentation
Earnings · 22 slides · Aug 6, 2026
Q1 2026 Earnings Presentation
Earnings · 29 slides · May 7, 2026
Q4 2025 Earnings Presentation
Earnings · 31 slides · Mar 5, 2026
Lexicon Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 37 in the last 12 months · 202 in all · newest Oct 21, 2026 · oldest 2019
- Calls
- 18 calls with a replay · 18 with a transcript · latest Aug 6, 2026
- Decks
- 18 decks · latest September 2026
Where Lexicon Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LXRX · Home listing | NASDAQ | United States | USD |
| Tradegate:LX31 · This page | Tradegate | Germany | EUR |
| BOATS:LXRX | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Lexicon Pharmaceuticals, Inc.